Similar Posts
Ultragenyx CEO talks the company’s path to profitability in developing drugs for rare diseases
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Dr. Emil Kakkis, Ultragenyx founder & CEO, joins ‘Closing Bell Overtime’ to talk drug trials and development, its path to profitability and more.
Customs union has not helped UK firms, economist says
Gerard Lyons tells CNBC there is too much fear about leaving the EU without a deal.
How one options trader is riding Uber to the long side
The ‘Options Action’ traders talk Uber strategy.
GM’s McNeill on EV market: Headlines are disconnected from the data
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Jon McNeill, GM board member and former Tesla president, joins ‘Squawk on the Street’ to discuss why growth is not slowing in the electric vehicle market, if McNeill shares the popular worries for the EV market, and more.
Jim Cramer’s guide to investing: Pay attention to big insider buying
CNBC’s Jim Cramer said investors should usually wait until high-quality stocks have had a pullback before buying. But sometimes it’s worth buying some stock at the top, especially if a company engages in significant insider buying. Not to be confused with insider trading, insider buying is based on public information and occurs when executives buy…
Hacked? Identity stolen? Here’s what to do next
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email CNBC’s Kelli Grant outlines how you can keep your identity safe from theft or fraud and what you can do should your private information become compromised. 01:30 Mon, Jul 20 20155:00 AM EDT
